Advertisement

American Journal of Clinical Dermatology

, Volume 9, Issue 2, pp 71–92 | Cite as

Clinical Approach to Cutaneous Vasculitis

  • Ko-Ron Chen
  • J. Andrew Carlson
Therapy in Practice Clinical Approach to Cutaneous Vasculitis

Abstract

Vasculitis is an inflammatory process affecting the vessel wall and leading to its compromise or destruction and subsequent hemorrhagic and ischemic events. Vasculitis can be classified as a primary phenomenon (e.g. idiopathic cutaneous leukocytoclastic angiitis or Wegener granulomatosis) or as a secondary disorder (connective tissue disease [CTD], infection, or adverse drug eruption-associated vasculitis). Cutaneous vasculitis may present as a significant component of many systemic vasculitic syndromes such as rheumatoid vasculitis or anti-neutrophil cytoplasmic antibody (ANCA)-associated primary vasculitic syndromes (Wegener granulomatosis, Churg-Strauss syndrome, microscopic polyangiitis). Cutaneous vasculitis manifests most frequently as palpable purpura or infiltrated erythema indicating dermal superficial, small-vessel vasculitis, and less commonly as nodular erythema, livedo racemosa, deep ulcers, or digital gangrene implicating deep dermal or subcutaneous, muscular-vessel vasculitis. A biopsy extending to the subcutis taken from the most tender, reddish or purpuric lesional skin is the key to obtaining a significant diagnostic result and serial sections are often required for identifying the main vasculitic lesion. Coexistence of pan-dermal small-vessel vasculitis and subcutaneous muscular-vessel vasculitis usually indicates CTD, ANCA-associated vasculitis, Behçet disease, or malignancy-associated vasculitis. A concomitant biopsy for direct immunofluoresence evaluation contributes to accurate diagnosis by distinguishing IgA-associated vasculitis (Henoch-Schönlein purpura) from IgG-/IgM-associated vasculitis, which has prognostic significance. Treatment for cutaneous vasculitis should include avoidance of triggers (excessive standing, infection, drugs) and exclusion of vasculitis-like syndromes (pseudovasculitis) such as thrombotic disorders (e.g. anti-phospholipid antibody syndrome). In most instances, cutaneous vasculitis represents a self-limited condition and will be relieved by leg elevation, avoidance of standing, and therapy with NSAIDs. For mild recurrent or persistent disease, colchicine and dapsone are first-choice agents. Severe cutaneous disease requires treatment with systemic corticosteroids or more potent immunosuppression (azathioprine, methotrexate, cyclophosphamide). A combination of corticosteroids and cyclophosphamide is required therapy for systemic vasculitis, which is associated with a high risk of permanent organ damage or death. In cases of refractory vasculitis, plasmapheresis and intravenous immunoglobulin are viable considerations. The new biologic therapies that act via cytokine blockade or lymphocyte depletion, such as the tumor necrosis factor-α inhibitor infliximab and the anti-B-cell antibody rituximab, respectively, are showing benefit in certain settings such as CTD and ANCA-associated vasculitis.

Keywords

Vasculitis Giant Cell Arteritis Systemic Vasculitis Cutaneous Vasculitis Urticarial Vasculitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.

References

  1. 1.
    Carlson JA, Cavaliere LF, Grant-Kels JM. Cutaneous vasculitis: diagnosis and management. Clin Dermatol 2006 Sep-Oct; 24 (5): 414–29PubMedCrossRefGoogle Scholar
  2. 2.
    Carlson JA, Chen KR. Cutaneous vasculitis update: small vessel neutrophilic vasculitis syndromes. Am J Dermatopathol 2006 Dec; 28 (6): 486–506PubMedCrossRefGoogle Scholar
  3. 3.
    Carlson JA, Chen KR. Cutaneous vasculitis update: neutrophilic muscular vessel and eosinophilic, granulomatous, and lymphocytic vasculitis syndromes. Am J Dermatopathol 2007 Feb; 29 (1): 32–43PubMedCrossRefGoogle Scholar
  4. 4.
    Carlson JA, Ng BT, Chen KR. Cutaneous vasculitis update: diagnostic criteria, classification, epidemiology, etiology, pathogenesis, evaluation and prognosis. Am J Dermatopathol 2005 Dec; 27 (6): 504–28PubMedCrossRefGoogle Scholar
  5. 5.
    Grzeszkiewicz TM, Fiorentino DF. Update on cutaneous vasculitis. Semin Cutan Med Surg 2006 Dec; 25 (4): 221–5PubMedCrossRefGoogle Scholar
  6. 6.
    Lapraik C, Watts R, Scott DG. Modern management of primary systemic vasculitis. Clin Med 2007 Jan-Feb; 7 (1): 43–7PubMedGoogle Scholar
  7. 7.
    Russell JP, Gibson LE. Primary cutaneous small vessel vasculitis: approach to diagnosis and treatment. Int J Dermatol 2006 Jan; 45 (1): 3–13PubMedCrossRefGoogle Scholar
  8. 8.
    Carlson JA, Chen KR. Cutaneous pseudovasculitis. Am J Dermatopathol 2007 Feb; 29 (1): 44–55PubMedCrossRefGoogle Scholar
  9. 9.
    Sunderkotter C, Bonsmann G, Sindrilaru A. Management of leukocytoclastic vasculitis. J Dermatolog Treat 2005 Sep; 16 (4): 193–206PubMedCrossRefGoogle Scholar
  10. 10.
    Sunderkotter C, Sindrilaru A. Clinical classification of vasculitis. Eur J Dermatol 2006 Mar-Apr; 16 (2): 114–24PubMedGoogle Scholar
  11. 11.
    Piette W. Primary systemic vasculitis. In: Sontheimer RD, Provost TT, editors Cutaneous manifestations of systemic diseases Philadelphia (PA): Lippincott Williams & Wilkins, 2004 159–95Google Scholar
  12. 12.
    Sneller MC, Langford CA, Fauci AS. The vasculitic syndromes. In: Kasper Kasper DL, Braunwald E, Fauci AS, editors. Harrison’s principles of internal medicine. 16th edition; New York: McGraw-Hill, 2005Google Scholar
  13. 13.
    Lane SE, Watts RA, Shepstone L. Primary systemic vasculitis: clinical features and mortality. QJM 2005 Feb; 98 (2): 97–111PubMedCrossRefGoogle Scholar
  14. 14.
    Ramos-Casals M, Nardi N, Lagrutta M. Vasculitis in systemic lupus erythematosus: prevalence and clinical characteristics in 670 patients. Medicine (Baltimore) 2006 Mar; 85 (2): 95–104CrossRefGoogle Scholar
  15. 15.
    Chen KR, Toyohara A, Suzuki A. Clinical and histopathological spectrum of cutaneous vasculitis in rheumatoid arthritis. Br J Dermatol 2002 Nov; 147 (5): 905–13PubMedCrossRefGoogle Scholar
  16. 16.
    Jennette JC, Falk RJ, Andrassy K. Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum 1994 37 (2): 187–92PubMedCrossRefGoogle Scholar
  17. 17.
    Fries JF, Hunder GG, Bloch DA. The American College of Rheumatology 1990 criteria for the classification of vasculitis: summary. Arthritis Rheum 1990 Aug; 33 (8): 1135–6PubMedCrossRefGoogle Scholar
  18. 18.
    Leavitt RY, Fauci AS, Bloch DA. The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum 1990 Aug; 33 (8): 1101–7PubMedCrossRefGoogle Scholar
  19. 19.
    Masi AT, Hunder GG, Lie JT. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990 Aug; 33 (8): 1094–100PubMedCrossRefGoogle Scholar
  20. 20.
    Hunder GG, Bloch DA, Michel BA. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990 Aug; 33 (8): 1122–8PubMedCrossRefGoogle Scholar
  21. 21.
    Mills JA, Michel BA, Bloch DA. The American College of Rheumatology 1990 criteria for the classification of Henoch-Sch¨ onlein purpura. Arthritis Rheum 1990 Aug; 33 (8): 1114–21PubMedCrossRefGoogle Scholar
  22. 22.
    Calabrese LH, Michel BA, Bloch DA. The American College of Rheumatology 1990 criteria for the classification of hypersensitivity vasculitis. Arthritis Rheum 1990 Aug; 33 (8): 1108–13PubMedCrossRefGoogle Scholar
  23. 23.
    Lightfoot Jr RW, Michel BA, Bloch DA. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum 1990 Aug; 33 (8): 1088–93PubMedCrossRefGoogle Scholar
  24. 24.
    Arend WP, Michel BA, Bloch DA. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 1990 Aug; 33 (8): 1129–34PubMedCrossRefGoogle Scholar
  25. 25.
    Callen JP. Cutaneous vasculitis: what have we learned in the past 20 years? Arch Dermatol 1998; 134 (3): 355–7PubMedCrossRefGoogle Scholar
  26. 26.
    Rao JK, Allen NB, Pincus T. Limitations of the 1990 American College of Rheumatology classification criteria in the diagnosis of vasculitis. Ann Intern Med 1998 Sep 1; 129 (5): 345–52PubMedGoogle Scholar
  27. 27.
    Martinez-Taboada VM, Blanco R, Garcia-Fuentes M. Clinical features and outcome of 95 patients with hypersensitivity vasculitis. Am J Med 1997 Feb; 102 (2): 186–91PubMedCrossRefGoogle Scholar
  28. 28.
    Jennette JC, Falk RJ. Do vasculitis categorization systems really matter? Curr Rheumatol Rep 2000; 2 (5): 430–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Watts RA, Scott DG. Classification and epidemiology of the vasculitides. Baillieres Clin Rheumatol 1997 11 (2): 191–217PubMedCrossRefGoogle Scholar
  30. 30.
    Pillebout E, Thervet E, Hill G. Henoch-Sch¨ onlein purpura in adults: outcome and prognostic factors. J Am Soc Nephrol 2002 May; 13 (5): 1271–8PubMedCrossRefGoogle Scholar
  31. 31.
    Tai YJ, Chong AH, Williams RA. Retrospective analysis of adult patients with cutaneous leukocytoclastic vasculitis. Australas J Dermatol 2006 May; 47 (2): 92–6PubMedCrossRefGoogle Scholar
  32. 32.
    Ioannidou DJ, Krasagakis K, Daphnis EK. Cutaneous small vessel vasculitis: an entity with frequent renal involvement. Arch Dermatol 2002 Mar; 138 (3): 412–4PubMedCrossRefGoogle Scholar
  33. 33.
    Magro CM, Crowson AN. A clinical and histologic study of 37 cases of immunoglobulin A-associated vasculitis. Am J Dermatopathol 1999 21 (3): 234–40PubMedCrossRefGoogle Scholar
  34. 34.
    Grau R. Pseudovasculitis: mechanisms of vascular injury and clinical spectrum. Curr Rheumatol Rep 2002 Feb; 4 (1): 83–9PubMedCrossRefGoogle Scholar
  35. 35.
    Ricotti C, Kowalczyk JP, Ghersi M. The diagnostic yield of histopathologic sampling techniques in PAN-associated cutaneous ulcers. Arch Dermatol 2007 143 (10): 1334–6PubMedCrossRefGoogle Scholar
  36. 36.
    Sais G, Vidaller A, Jucgla A. Prognostic factors in leukocytoclastic vasculitis: a clinicopathologic study of 160 patients. Arch Dermatol 1998 134 (3): 309–15PubMedCrossRefGoogle Scholar
  37. 37.
    Barnadas MA, Perez E, Gich I. Diagnostic, prognostic and pathogenic value of the direct immunofluorescence test in cutaneous leukocytoclastic vasculitis. Int J Dermatol 2004 Jan; 43 (1): 19–26PubMedCrossRefGoogle Scholar
  38. 38.
    Fiorentino DF. Cutaneous vasculitis. J Am Acad Dermatol 2003 Mar; 48 (3): 311–40PubMedCrossRefGoogle Scholar
  39. 39.
    Toyohara A, Chen KR, Miyakawa S. A case of leukocytoclastic vasculitis associated infective endocarditis. Jpn J Clin Dermatol 1997 51: 225–7Google Scholar
  40. 40.
    Eisenberger U, Fakhouri F, Vanhille P. ANCA-negative pauci-immune renal vasculitis: histology and outcome. Nephrol Dial Transplant 2005 20 (7): 1392–9PubMedCrossRefGoogle Scholar
  41. 41.
    Khilnani GC, Banga A, Sharma SC. Wegener’s granulomatosis: an isolated lung mass responding to antituberculosis therapy and atypical course. J Assoc Physicians India 2003 Jul; 51: 731–3PubMedGoogle Scholar
  42. 42.
    Dammacco F, Sansonno D, Piccoli C. The cryoglobulins: an overview. Eur J Clin Invest 2001 Jul; 31 (7): 628–38PubMedCrossRefGoogle Scholar
  43. 43.
    Chen KR. Cutaneous polyarteritis nodosa: a clinical and histopathological study of 20 cases. J Dermatol 1989 Dec; 16 (6): 429–42PubMedGoogle Scholar
  44. 44.
    Minkowitz G, Smoller BR, McNutt NS. Benign cutaneous polyarteritis nodosa: relationship to systemic polyarteritis nodosa and to hepatitis B infection. Arch Dermatol 1991 127 (10): 1520–3PubMedCrossRefGoogle Scholar
  45. 45.
    Davis MD, Daoud MS, Kirby B. Clinicopathologic correlation of hypocomplementemic and normocomplementemic urticarial vasculitis. J Am Acad Dermatol 1998 38 (6Pt1): 899–905PubMedGoogle Scholar
  46. 46.
    Drenkard C, Villa AR, Reyes E. Vasculitis in systemic lupus erythematosus. Lupus 1997 6 (3): 235–42PubMedCrossRefGoogle Scholar
  47. 47.
    Diaz-Perez JL, Schroeter AL, Winkelmann RK. Cutaneous periarteritis nodosa: immunofluorescence studies. Arch Dermatol 1980 Jan; 116 (1): 56–8PubMedCrossRefGoogle Scholar
  48. 48.
    Ratnam KV, Boon YH, Pang BK. Idiopathic hypersensitivity vasculitis: clinicopathologic correlation of 61 cases. Int J Dermatol 1995 Nov; 34 (11): 786–9PubMedCrossRefGoogle Scholar
  49. 49.
    Watts RA, Jolliffe VA, Grattan CE. Cutaneous vasculitis in a defined population: clinical and epidemiological associations. J Rheumatol 1998 25 (5): 920–4PubMedGoogle Scholar
  50. 50.
    Tancrede-Bohin E, Ochonisky S, Vignon-Pennamen MD. Henoch-Sch¨ onlein purpura in adult patients: predictive factors for IgA glomerulonephritis in a retrospective study of 57 cases. Arch Dermatol 1997 Apr; 133 (4): 438–42PubMedCrossRefGoogle Scholar
  51. 51.
    Hodge SJ, Callen JP, Ekenstam E. Cutaneous leukocytoclastic vasculitis: correlation of histopathological changes with clinical severity and course. J Cutan Pathol 1987 Oct; 14 (5): 279–84PubMedCrossRefGoogle Scholar
  52. 52.
    Cribier B, Couilliet D, Meyer P. The severity of histopathological changes of leukocytoclastic vasculitis is not predictive of extracutaneous involvement. Am J Dermatopathol 1999 21 (6): 532–6PubMedCrossRefGoogle Scholar
  53. 53.
    Chen KR, Kawahara Y, Miyakawa S. Cutaneous vasculitis in Behcet’s disease: a clinical and histopathologic study of 20 patients. J Am Acad Dermatol 1997 36 (5Pt1): 689–96PubMedCrossRefGoogle Scholar
  54. 54.
    Sanchez NP, Van Hale HM, Su WP. Clinical and histopathologic spectrum of necrotizing vasculitis: report of findings in 101 cases. Arch Dermatol 1985 Feb; 121 (2): 220–4PubMedCrossRefGoogle Scholar
  55. 55.
    Lerner L, Lio P, Flotte T. The prognostic significance of vascular immunoglobulin deposits in 94 cases of cutaneous leukocytoclastic vasculitis [abstract]. J Cutan Pathol 2000 27: 562Google Scholar
  56. 56.
    Mehregan DR, Hall MJ, Gibson LE. Urticarial vasculitis: a histopathologic and clinical review of 72 cases. J Am Acad Dermatol 1992 Mar; 26 (3Pt2): 441–8PubMedCrossRefGoogle Scholar
  57. 57.
    Lynch JM, Barrett TL. Collagenolytic (necrobiotic) granulomas: part 1. The “blue” granulomas J Cutan Pathol 2004 May; 31 (5): 353–61Google Scholar
  58. 58.
    Lynch JM, Barrett TL. Collagenolytic (necrobiotic) granulomas: part II. The “red” granulomas J Cutan Pathol 2004 Jul; 31 (6): 409–18Google Scholar
  59. 59.
    Bahrami S, Malone JC, Webb KG. Tissue eosinophilia as an indicator of drug-induced cutaneous small-vessel vasculitis. Arch Dermatol 2006 Feb; 142 (2): 155–61PubMedCrossRefGoogle Scholar
  60. 60.
    Kelly RI, Opie J, Nixon R. Golfer’s vasculitis. Australas J Dermatol 2005 Feb; 46 (1): 11–4PubMedCrossRefGoogle Scholar
  61. 61.
    Ramelet AA. Exercise-induced vasculitis. J Eur Acad Dermatol Venereol 2006 Apr; 20 (4): 423–7PubMedCrossRefGoogle Scholar
  62. 62.
    Blanco R, Martinez-Taboada VM, Rodriguez-Valverde V. Cutaneous vasculitis in children and adults: associated diseases and etiologic factors in 303 patients. Medicine (Baltimore) 1998 77 (6): 403–18CrossRefGoogle Scholar
  63. 63.
    Narchi H. Risk of long term renal impairment and duration of follow-up recommended for Henoch-Sch¨ onlein purpura with normal or minimal urinary findings: a systematic review. Arch Dis Child 2005 Sep; 90 (9): 916–20PubMedCrossRefGoogle Scholar
  64. 64.
    Goldstein AR, White RH, Akuse R. Long-term follow-up of childhood Henoch-Sch¨ onlein nephritis. Lancet 1992 Feb 1; 339 (8788): 280–2PubMedCrossRefGoogle Scholar
  65. 65.
    ten Holder SM, Joy MS, Falk RJ. Cutaneous and systemic manifestations of drug-induced vasculitis. Ann Pharmacother 2002 Jan; 36 (1): 130–47PubMedCrossRefGoogle Scholar
  66. 66.
    Kudoh Y, Kuroda S, Shimamoto K. Propylthiouracil-induced rapidly progressive glomerulonephritis associated with antineutrophil cytoplasmic autoanti-bodies. Clin Nephrol 1997 Jul; 48 (1): 41–3PubMedGoogle Scholar
  67. 67.
    Alon U, Hellerstein S, Warady BA. Anti-neutrophil cytoplasmatic antibodies in drug-induced Wegener-like disease. Pediatr Nephrol 1990 May; 4 (3): 299–300PubMedGoogle Scholar
  68. 68.
    Martinez-Vea A, Ferrer I, Carcia C. Systemic vasculitis resembling periarteritis nodosa in the lupus-like syndrome induced by hydralazine. Am J Nephrol 1987 7 (1): 71–3PubMedCrossRefGoogle Scholar
  69. 69.
    Davis MD, Brewer JD. Urticarial vasculitis and hypocomplementemic urticarial vasculitis syndrome. Immunol Allergy Clin North Am 2004 May; 24 (2): 183–213PubMedCrossRefGoogle Scholar
  70. 70.
    Sunderkotter C, Seeliger S, Schonlau F. Different pathways leading to cutaneous leukocytoclastic vasculitis in mice. Exp Dermatol 2001 Dec; 10 (6): 391–404PubMedCrossRefGoogle Scholar
  71. 71.
    Scherer R, Braun-Falco O. Alternative pathway complement activation: a possible mechanism inducing skin lesions in benign gonococcal sepsis. Br J Dermatol 1976 Sep; 95 (3): 303–9PubMedCrossRefGoogle Scholar
  72. 72.
    Belmont HM, Abramson SB, Lie JT. Pathology and pathogenesis of vascular injury in systemic lupus erythematosus: interactions of inflammatory cells and activated endothelium. Arthritis Rheum 1996 Jan; 39 (1): 9–22PubMedCrossRefGoogle Scholar
  73. 73.
    Carlson JA, Mihm Jr MC, LeBoit PE. Cutaneous lymphocytic vasculitis: a definition, a review, and a proposed classification. Semin Diagn Pathol 1996 13 (1): 72–90PubMedGoogle Scholar
  74. 74.
    Davis MD, Daoud MS, McEvoy MT. Cutaneous manifestations of Churg-Strauss syndrome: a clinicopathologic correlation. J Am Acad Dermatol 1997 37 (2Pt1): 199–203PubMedCrossRefGoogle Scholar
  75. 75.
    Kallenberg CG. Antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis. Curr Opin Rheumatol 2007 Jan; 19 (1): 17–24PubMedCrossRefGoogle Scholar
  76. 76.
    Chen KR, Ohata Y, Sakurai M. Churg-Strauss syndrome: report of a case without preexisting asthma. J Dermatol 1992 Jan; 19 (1): 40–7PubMedGoogle Scholar
  77. 77.
    Chen KR, Sakamoto M, Ikemoto K. Granulomatous arteritis in cutaneous lesions of Churg-Strauss syndrome. J Cutan Pathol 2007 Apr; 34 (4): 330–7PubMedCrossRefGoogle Scholar
  78. 78.
    Mimouni D, Ng PP, Rencic A. Cutaneous polyarteritis nodosa in patients presenting with atrophie blanche. Br J Dermatol 2003 Apr; 148 (4): 789–94PubMedCrossRefGoogle Scholar
  79. 79.
    Dewar CL, Bellamy N. Necrotizing mesenteric vasculitis after longstanding cutaneous polyarteritis nodosa. J Rheumatol 1992 Aug; 19 (8): 1308–11PubMedGoogle Scholar
  80. 80.
    Orton DI, Whittaker SJ. Renal angiogram abnormalities in a case of cutaneous polyarteritis nodosa. Clin Exp Dermatol 2000 Jan; 25 (1): 33–5PubMedCrossRefGoogle Scholar
  81. 81.
    Dalton SR, Fillman EP, Ferringer T. Smooth muscle pattern is more reliable than the presence or absence of an internal elastic lamina in distinguishing an artery from a vein. J Cutan Pathol 2006 Mar; 33 (3): 216–9PubMedCrossRefGoogle Scholar
  82. 82.
    Yus ES, Simon P. About the histopathology of erythema induratum-nodular vasculitis. Am J Dermatopathol 1999 Jun; 21 (3): 301–6PubMedCrossRefGoogle Scholar
  83. 83.
    Bosch X, Guilabert A, Espinosa G. Treatment of antineutrophil cytoplasmic antibody associated vasculitis: a systematic review. JAMA 2007 Aug 8; 298 (6): 655–69PubMedCrossRefGoogle Scholar
  84. 84.
    Russell JP, Weenig RH. Primary cutaneous small vessel vasculitis. Curr Treat Options Cardiovasc Med 2004 Apr; 6 (2): 139–49PubMedCrossRefGoogle Scholar
  85. 85.
    Cohen P, Pagnoux C, Mahr A. Churg-Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum 2007 Apr 30; 57 (4): 686–93PubMedCrossRefGoogle Scholar
  86. 86.
    Guillevin L, Cohen P, Mahr A. Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial com- paring glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis Rheum 2003 Feb 15; 49 (1): 93–100PubMedCrossRefGoogle Scholar
  87. 87.
    Gonzalez-Fernandez MA, Garcia-Consuegra J. Polyarteritis nodosa resistant to conventional treatment in a pediatric patient. Ann Pharmacother 2007 May; 41 (5): 885–90PubMedCrossRefGoogle Scholar
  88. 88.
    Suresh E. Diagnostic approach to patients with suspected vasculitis. Postgrad Med J 2006 Aug; 82 (970): 483–8PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  • Ko-Ron Chen
    • 1
  • J. Andrew Carlson
    • 2
  1. 1.Department of DermatologySaiseikai Central HospitalTokyoJapan
  2. 2.Divisions of Dermatology and DermatopathologyAlbany Medical College MC-81AlbanyUSA

Personalised recommendations